Skip to main content
SpringerLink
Log in

Pharmaka zur Behandlung der Herzinsuffizienz

  • Chapter
Pharmakologie und Toxikologie

Part of the book series: Springer-Lehrbuch ((SLB))

  • 885 Accesses

Zusammenfassung

Auf zellulärer Ebene beginnt die Kontraktion mit der vom Sinusknoten ausgehenden Erregungswelle, die an der Membran der Herzmuskelzelle ein Aktionspotential auslöst. Dem elektrischen Phänomen des Aktionspotentials liegen Ionenbewegungen an der Zellmembran zugrunde, die sich am Myokard und Erregungsleitungssystem unterscheiden (s. Kap. 19). An der Herzmuskelzelle beginnt das Aktionspotential mit der Öffnung von Natriumkanälen. Natrium strömt entsprechend dem Gradienten aus dem Extrazellularraum in die Zelle ein und depolarisiert die Zelle (s.Abb. 18.1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Beukelmann DJ, Erdmann E (1994) Digitalistherapie 1994. Internist 35:872–876

    Google Scholar 

  • Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316:1429–1435

    Article  Google Scholar 

  • Deutsche Gesellschaft für Kardiologie (1998) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 87:645–658

    Google Scholar 

  • Eisner DA, Lederer WJ (1985) Na-Ca exchange: stoichiometry and electrogenicity. Am J Physiol 248:C189–C202

    PubMed  CAS  Google Scholar 

  • Feldman AM, Bristow MR, Parmely WW et al. (1993) Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 329:149–155

    Article  PubMed  CAS  Google Scholar 

  • Fischer TA, Erbel R, Treese N (1992) Current status of phosphodiesterase inhibitor treatment of congestive heart failure. Drugs 44:928–945

    Article  PubMed  Google Scholar 

  • Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273:1450–1456

    Article  PubMed  CAS  Google Scholar 

  • Groden DL (1993) Vasodilator therapy for congestive heart failure. Arch Intern Med 153:445–454

    Article  PubMed  CAS  Google Scholar 

  • Kim D, Cragoe ED Jr, Smith TW (1987) Relations among sodium pump, Na-Ca exchange activities, and Ca-H interaction in cultured chick heart cells. Circ Res 60:185–193

    Article  PubMed  CAS  Google Scholar 

  • Kramer W, Waas W, Tillmanns H (1991) Therapie der chronischen Herzinsuffizienz. Langfristige Aspekte. Arzneimitteltherapie 9:102–110

    Google Scholar 

  • Leyen H von der, Meyer W (1991) Phosphodiesterase III-Hemmstoffe in der Therapie der Herzinsuffizienz. Arzneimitteltherapie 9:42–55

    Google Scholar 

  • Lindsay SJ, Kearney MT, Prescott RJ ,et al (1999) Digoxin and mortality in chronic heart failure. UK Heart Investigation. Lancet 354:1003

    Article  PubMed  CAS  Google Scholar 

  • McMurray JJ (1999) Major beta blocker trials in chronic heart failure: a critical review. Heart 82 Suppl 4:14–22

    Google Scholar 

  • Mooradian AD (1988) Digitalis: an update of clinical pharmacokinetics, therapeutic monitoring techniqes, and treatment recommendations. Clin Pharmacokinet 15:165–179

    Article  PubMed  CAS  Google Scholar 

  • Packer M, Carver JR, Rodeheffer RJ et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325:1468–1474

    Article  PubMed  CAS  Google Scholar 

  • Packer M, Gheorghiade M, Young JB et al. (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 329:1–7

    Article  PubMed  CAS  Google Scholar 

  • Packer M (1998) Beta-blockade in heart failure. Basic concepts and clinical results. Am J Hypertens 11: 23S – 37S

    Article  PubMed  CAS  Google Scholar 

  • Pfaffendorf M (1997) Neue positiv inotrope Stoffe. Med Mo Pharm 20:205–217 (PDE-Hemmer, Calcium-sensitizer, K+Kanalmodulatoren)

    CAS  Google Scholar 

  • Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluations. Study investigators. N Engl J Med 341:709–717 (RALESS-tudie)

    Article  PubMed  CAS  Google Scholar 

  • Pitt B, Poole-Wilson PA, Segal R et al. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587

    Article  PubMed  CAS  Google Scholar 

  • Praktische Aspekte der Therapie mit Angiotensinkonversionsenzymen (ACE)-Hemmern (1994) Arzneimittelbrief 28:25–30

    Google Scholar 

  • Riaz K, Forker AD (1998) Digoxin use in congestive heart failure. Current status. Drugs 55:747–758

    Article  PubMed  CAS  Google Scholar 

  • Scholz H (1984) Inotropic drugs and their mechanism of action. J Am Coll Cardiol 4:389–397

    Article  PubMed  CAS  Google Scholar 

  • Sitzler G, Stäblein A, Böhm M (1996) Diastolische Dysfunktion des Herzens. Dtsch Med Wochenschr 121:70–76

    Article  PubMed  CAS  Google Scholar 

  • SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325:293–302

    Article  Google Scholar 

  • Stevenson LW, Fonarow G (1992) Vasodilators. A re-evaluation of their role in heart failure. Drugs 43:15–36

    Article  PubMed  CAS  Google Scholar 

  • Strauer BE (Herausgeber)(1993) Herzinsuffizienz. Internist 34:885–961

    Google Scholar 

  • Task Force of the Working Group in Heart Failure of the European Society of Cardiology (1997) Guidelines. The treatment of heart failure. Eur Heart J 18: 738–753

    Google Scholar 

  • The ALLHAT Officers and Coordinators, for the ALLHAT Collaborative Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs. placebo. JAMA 283:1967–1975

    Article  Google Scholar 

  • The Digitalis Investigators (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533

    Article  Google Scholar 

  • The Heart Outcomes Prevention Evaluation Investigators (2000) Effect of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153 (HOPE-Studie)

    Article  Google Scholar 

  • Thormann J, Mitrovic V, Bohavar H (1998) Therapiekonzepte der Herzinsuffizienz mit neuen Substanzen. Herz-Kreislauf 30:382–392 (Levosimendan, Moxonidin, Tedisamil, Endothelin-Antagonisten)

    Google Scholar 

  • Trenk D (2000) Ergebnisse der HOPE-Studie. Arzneimitteltherapie 18:138–140

    Google Scholar 

  • Weber KT (editor)(1987) The use of enoximone in heart failure. Am J Cardiol 60:1C–90C

    Google Scholar 

Download references

Authors
  1. E. Hackenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fachbereich Humanmedizin — Institut für Pharmakologie, Freie Universität Berlin, Thielallee 67-73, 14195, Berlin, Germany

    Eckard Oberdisse

  2. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany

    Eberhard Hackenthal

  3. Institut für Pharmakologie und Toxikologie, Universität Marburg/Lahn, Ketzerbach 63, 35032, Marburg, Germany

    Klaus Kuschinsky

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hackenthal, E. (2002). Pharmaka zur Behandlung der Herzinsuffizienz. In: Oberdisse, E., Hackenthal, E., Kuschinsky, K. (eds) Pharmakologie und Toxikologie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56314-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56314-0_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62634-0

  • Online ISBN: 978-3-642-56314-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation